Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 3
Submit an article Journal homepage
992
Views
5
CrossRef citations to date
0
Altmetric
Letters to the Editor

Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?

Imane Saad Albichra Department of Microbiology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, BelgiumCorrespondence[email protected]
,
Julien De Greefb Department of Internal Medicine and Infectious Disease, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
,
Eric Van Den Nestec Department of Hematology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
,
Xavier Poiréc Department of Hematology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
,
Violaine Havelangec Department of Hematology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
,
Marie-Christiane Vekemansc Department of Hematology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
,
Sarah Baillyc Department of Hematology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
,
Jean-Cyr Yombib Department of Internal Medicine and Infectious Disease, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
,
Samy Mzouguia Department of Microbiology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
,
Anaïs Scohya Department of Microbiology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
&
Benoît Kabamba-Mukadia Department of Microbiology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
 show all
Pages 743-746 | Received 29 Aug 2021, Accepted 12 Oct 2021, Published online: 28 Oct 2021

References

  • Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 Vaccines. JAMA. 2021;325(13):1318–1320.
  • Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and Meta-analysis of 3377 patients. Blood. 2020;136(25):2881–2892.
  • Maneikis K, Šablauskas K, Ringelevičiūtė U, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8(8):e583–e592.
  • Agha M, Blake M, Chilleo C, et al. Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. medRxiv. 2021. 2021.04.06.21254949.
  • Addeo A, Shah PK, Bordry N, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021;39(8):1091–1098.e2.
  • Ong DSY, Fragkou PC, Schweitzer VA, et al. How to interpret and use COVID-19 serology and immunology tests. Clin Microbiol Infect. 2021;27(7):981–986.
  • Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–3173.
  • Mrak D, Tobudic S, Koblischke M, et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis. 2021;80(10):1345–1350.
  • Monin L, Laing AG, Muñoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765–778.
  • Mariotti J, Spina F, Carniti C, et al. Long-term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies. Eur J Haematol. 2012;89(2):111–119.
  • de Lavallade H, Garland P, Sekine T, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica. 2011;96(2):307–314.
  • Dagnew AF, Ilhan O, Lee W-S, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988–1000.
  • Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861–880.
  • Duléry R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96(8):934–944.
  • Huzly D, Panning M, Smely F, et al. Validation and performance evaluation of a novel interferon-γ release assay for the detection of SARS-CoV-2 specific T-cell response [Internet] 2021; [cited 2021 Aug 25]. p. 2021.07.17.21260316. Available from: https://www.medrxiv.org/content/10.1101/2021.07.17.21260316v1.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.